FOXO4-DRI is a synthetic 46-residue retro-inverso peptide, built from D-amino acids and fused to a cell-penetrating import sequence, that is used in laboratory research as a chemical probe for the FOXO4-p53 protein interaction in senescent cells. It was first described by Baar and colleagues in Cell in 2017, where disrupting that interaction released p53 from FOXO4 sequestration and triggered apoptosis preferentially in senescent cells rather than in proliferating or quiescent ones. This article reviews the compound's design, mechanism, published pre-clinical literature through 2026, known limitations, and laboratory handling. All information is provided strictly for in-vitro and laboratory research use only.
What Is FOXO4-DRI?
FOXO4 (forkhead box O transcription factor 4) is a member of the FOXO family of transcription factors. In cells that have entered a senescent state, FOXO4 becomes elevated and binds the tumour-suppressor protein p53, holding it in nuclear foci and preventing it from initiating the apoptotic program. Because senescent cells accumulate DNA damage that would normally push p53 toward apoptosis, this sequestration is one of the mechanisms by which such cells remain viable instead of dying — the state sometimes described as apoptosis resistance.
FOXO4-DRI ("DRI" = D-Retro-Inverso) was engineered as a competitive interference peptide against that interaction. Two design choices define it:
- Retro-inverso architecture. The sequence order is reversed and every residue is a D-amino acid rather than the naturally occurring L form. This preserves an approximate topological mimic of the parent side-chain arrangement while making the peptide highly resistant to proteolytic degradation.
- Cell-penetrating fusion. A basic HIV TAT-derived import sequence is appended so the peptide can cross the plasma membrane and reach the nuclear compartment where FOXO4 and p53 interact.
Mechanism of Action
The FOXO4-p53 axis
The mechanistic logic reported in the literature runs as follows. Senescent cells upregulate FOXO4. FOXO4 binds p53 and restrains its pro-apoptotic transcriptional activity. FOXO4-DRI competes for the same binding surface, displacing endogenous FOXO4. Freed p53 undergoes nuclear exclusion, and mitochondrial apoptotic signalling proceeds. Baar et al. reported that this produced cell-intrinsic, p53-dependent death in senescent cells while largely sparing non-senescent populations in the same culture.
Structural refinement
The precise binding surface was ambiguous for several years. Two structural studies clarified it. Bourgeois and Madl (FEBS Letters, 2018) reviewed the biophysics of the FOXO4-p53 axis and the dual binding surfaces involved. More recently, Bourgeois and colleagues reported in Nature Communications (2025) that the intrinsically disordered p53 transactivation domain — rather than the DNA-binding core — is the principal target engaged both by FOXO4 and by FOXO4-DRI, providing a defined structural basis for the peptide's competitive activity and a template for designing shorter analogues.
Downstream signalling
A 2026 study in Frontiers in Bioengineering and Biotechnology characterised the downstream pathway in endothelial cells, reporting that FOXO4-DRI promoted nuclear export of phosphorylated p53 and drove apoptosis of senescent endothelial cells through a p53/BCL-2/caspase-3 signalling cascade.
Published Research Overview
The peer-reviewed record on FOXO4-DRI is entirely pre-clinical — cell culture and rodent models. Key studies:
- Baar et al., Cell, 2017 (169:132-147.e16). The originating paper. Reported targeted apoptosis of senescent cells and, in mouse models, restoration of markers of tissue homeostasis in fast-ageing and naturally aged animals, and in animals exposed to doxorubicin chemotoxicity.
- Zhang et al., Aging (Albany NY), 2020. Reported that FOXO4-DRI selectively induced apoptosis in senescent Leydig cells in aged mice and altered the testicular microenvironment in that model.
- Huang, He, Makarcyzk & Lin, Frontiers in Bioengineering and Biotechnology, 2021 (9:677576). An informative selectivity dataset. In serially expanded human chondrocytes, FOXO4-DRI removed more than half the cells at population-doubling level 9 (a senescence-enriched passage) but did not significantly change cell number at PDL3 (minimally expanded). In parallel work with human IMR90 fibroblasts, the reported reduction in viability was more than ten-fold greater in senescent than in non-senescent cells.
- Le et al., EBioMedicine, 2021 (72:103646). Used molecular modelling of the FOXO4-TP53 interface to design shorter senolytic peptides aimed at eliminating senescent cancer cells, using FOXO4-DRI as the reference compound.
- Han et al., Journal of Cellular and Molecular Medicine, 2022 (26:3269-3280). Applied the peptide in a bleomycin-induced pulmonary fibrosis mouse model, reporting reduced senescent-cell burden and downregulated senescence-associated secretory phenotype (SASP) expression, with an ECM-receptor interaction pathway implicated.
- Bourgeois et al., Nature Communications, 2025. Structural identification of the disordered p53 transactivation domain as the binding target (see above).
- Hu et al., Frontiers in Bioengineering and Biotechnology, 15 January 2026. The most recent primary study at time of writing: FOXO4-DRI regulated endothelial cell senescence via p53 signalling in naturally aged and induced-ageing mice, with effects reported on aortic ageing markers.
Limitations and Open Questions
Neutral reporting of this literature requires noting several constraints that investigators have raised:
- Target is a tumour suppressor. The mechanism works by modulating p53, a protein central to genome integrity. Reviews of the senolytics field flag the potential for on-target effects in non-senescent tissue as an unresolved question.
- Selectivity is relative, not absolute. The chondrocyte and IMR90 data describe a large but finite selectivity window — a greater than ten-fold difference in viability, not an all-or-nothing effect. Selectivity appears sensitive to cell type, senescence-induction method, and concentration.
- Synthesis cost and length. At 46 residues with all-D chemistry, the peptide is expensive to produce relative to small-molecule senolytics, which has motivated the shorter-analogue work cited above.
- No human clinical data. As of mid-2026, no completed or registered human clinical trial of FOXO4-DRI has been reported in the peer-reviewed literature. The FOXO4-p53 interaction is conserved in humans, which is why the mechanism is of interest, but conservation of a target is not evidence of clinical effect.
Storage & Handling
Dynamite Research Peptides supplies FOXO4-DRI as a lyophilized (freeze-dried) powder. Store the powder at -20°C or below, protected from light and moisture. Reconstitute immediately before use with a sterile solvent as indicated on the Certificate of Analysis (COA), keep reconstituted material refrigerated, and avoid repeated freeze-thaw cycles, which can compromise peptide integrity. Because the peptide is highly basic and cell-penetrating, prepare working solutions fresh and handle with appropriate personal protective equipment in a well-ventilated laboratory setting.
Conclusion
FOXO4-DRI is a well-characterised tool compound for interrogating the FOXO4-p53 axis, apoptosis resistance in senescent cells, and senolytic mechanism in vitro. Its value in a laboratory setting is mechanistic specificity: it targets a defined protein-protein interface whose structural basis was resolved in 2025. Our FOXO4-DRI is high-purity, third-party tested, and ships with a COA so experimental results stay reliable and reproducible.
Frequently Asked Questions
What is FOXO4-DRI?
It is a synthetic 46-residue D-retro-inverso peptide fused to a cell-penetrating sequence, designed to competitively disrupt the interaction between the transcription factor FOXO4 and the tumour suppressor p53. It is used as a research probe for cellular senescence and apoptosis pathways.
What does "D-retro-inverso" mean?
The residue order is reversed and all amino acids are the D-enantiomer instead of the natural L form. This yields a structural mimic of the parent peptide's side-chain topology while making it far more resistant to protease degradation than a conventional L-peptide.
How does FOXO4-DRI select for senescent cells?
Senescent cells upregulate FOXO4, which sequesters p53 and blocks apoptosis. Because non-senescent cells depend less on that interaction for survival, competitive displacement by FOXO4-DRI produces a much larger viability effect in senescent populations — reported as greater than ten-fold in senescent versus non-senescent IMR90 fibroblasts.
Has FOXO4-DRI been tested in humans?
No. As of 2026 the published record consists of cell-culture and rodent studies. No completed or registered human clinical trial has been reported in peer-reviewed literature.
What is the purity level of Dynamite Research Peptides' FOXO4-DRI?
Our FOXO4-DRI is typically 99%+ pure, verified by HPLC analysis. Detailed purity data is provided on the Certificate of Analysis (COA) included with each product.
What research applications is FOXO4-DRI suitable for?
In-vitro studies of cellular senescence and the senescence-associated secretory phenotype, FOXO4-p53 protein-protein interaction assays, p53-dependent apoptosis signalling, and comparative senolytic mechanism work.
All products are for research use only — not for human or animal consumption, and not for diagnostic or therapeutic use.